Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Fig. 5

Transforming growth factor beta receptor (TGFBR) and platelet-derived growth factor receptor beta (PDGFRB) signaling trends across nilotinib patients. a Expression trends for TGFBR signaling pathway across completers, improvers and non-improvers. b Expression trends for PDGFRB signaling pathway across completers, improvers and non-improvers. Scatter plots show mean with standard deviation

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us